UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 1822, 2026

MapLight Therapeutics, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-42914	83-2163243
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

800 Chesapeake Drive

Redwood City, California 94063

(Address of principal executive offices)

Registrant’s telephone number, including area code: (617) 984-6300

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Voting Common Stock, $0.0001 par value per share	MPLT	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 57.0201 ~~Departure~~Regulation ofFD ~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Disclosure.

On June 1822, 2026, ~~Vishwas Setia was separated as the Chief Financial Officer of~~ MapLight Therapeutics, Inc. (the “Company”), ~~effective~~will ~~immediately,~~hold ~~following~~ a ~~review~~conference ofcall to discuss the topline results from IRIS (ML-004-002), a ~~human~~Phase ~~resources~~2 ~~violation. Mr. Setia’s~~study ~~separation~~of ~~was~~ML-004 ~~wholly~~in ~~unrelated~~autism tospectrum disorder (the ~~Company’s~~“IRIS ~~financial~~Trial orResults”). ~~operating~~A ~~results,~~copy ~~internal~~of ~~controls~~the orpresentation ~~clinical~~that ~~programs,~~will oraccompany ~~any~~the ~~concerns~~conference orcall ~~disagreements~~is ~~regarding~~furnished ~~the~~herewith ~~Company’s~~as ~~financial~~Exhibit or99.1 ~~reporting~~to ~~practices~~this Current Report on Form 8-K.

~~Mr. Setia~~In ~~is not entitled to~~accordance ~~receive~~with ~~any severance payment~~General inInstruction ~~connection~~B.2. ~~with~~of ~~his~~Form ~~separation. However~~8-K, the ~~Company~~information in this Item 7.01 and MrExhibit 99. ~~Setia~~1 ~~entered~~hereto ~~into~~shall anot ~~Separation~~be ~~Agreement~~deemed on“filed” ~~June~~for purposes of Section 18, ~~2026~~of the Securities Exchange Act of 1934, ~~which~~as ~~contains~~amended (ithe “Exchange Act”) a, ~~release~~or otherwise subject to the liability of ~~claims~~that ~~against~~section, nor shall it be deemed incorporated by reference in any of the Company’s ~~and~~filings ~~(ii) payment~~under the Securities Act of ~~continued~~1933, ~~health~~as ~~coverage~~amended, ~~for~~or ~~Mr. Setia~~under ~~and~~the ~~his~~Exchange ~~dependents~~Act, ~~under~~whether ~~COBRA~~made ~~for~~before upor toafter ~~three~~the ~~months~~date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

~~The~~Item 8.01 ~~description~~Other of the Separation Agreement provided herein is not complete and is qualified in its entirety by reference to the Separation Agreement, which the Company intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2026Events.

InOn ~~connection with the separation of Mr.~~June ~~Setia~~22, ~~the board of directors of the Company appointed Jonathan Gillis~~2026, the Company’s ~~Chief~~issued ~~Administrative~~a ~~and~~press ~~Accounting~~release ~~Officer,~~announcing as the ~~Company’s~~IRIS ~~interim~~Trial ~~Chief Financial Officer and interim principal financial officer, effective June 18, 2026~~Results. ~~Mr. Gillis~~A ~~will~~copy ~~also~~of ~~continue~~this ~~his~~press ~~role~~release ~~as the Company’s principal accounting officer. Information regarding Mr. Gillis’s background and business experience~~ is ~~set forth under the caption “Executive Officers” in the Company’s definitive proxy statement~~ filed ~~with~~as ~~the~~Exhibit U99.S.2 ~~Securities~~to ~~and~~this ~~Exchange~~Current ~~Commission~~Report on ~~April 29,~~Form ~~2026,~~8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit Number		Exhibit Description

99.1		Company Presentation, dated June 22, 2026.

99.2		Press Release, dated June 22, 2026.

104		Cover Page Interactive Data File (formatted as inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MapLight Therapeutics, Inc.

Dated: June 18, 2026

/s/ Christopher A. Kroeger

Dated: June 22, 2026

/s/ Christopher A. Kroeger

Christopher A. Kroeger, M.D.

Chief Executive Officer

Filing Compare · MapLight Therapeutics, Inc.